Converting parathyroid hormone-related peptide (PTHrP) into a potent PTH-8 receptor agonist

Most of the bone and kidney-related functions of parathyroid hormone (PTH) and parathyroid hormone-related peptide (PTHrP) are thought to be mediated by the PTH/PTHrP receptor. Recently, a homologous receptor, the PTH-2 receptor, was obtained from rat and human brain cDNA libraries. This receptor displayed the remarkable property of responding potently to PTH, but not to PTHrP. To begin to define residues involved in the ligand specificity of the PTH-2 receptor, we studied the interaction of several PTH/PTHrP hybrid ligands and other related peptide analogs with the human PTH-2 receptor The results showed that two sites in PTH and PTHrP fully account for the different potencies that the tu o ligands exhibited with PTH-2 receptors; residue 5 (His in PTHrP and Ile in PTH) determined signaling capability, while residue 23 (Phe in PTHrP and Trp in PTH) determined binding affinity. By changing these two residues of PTHrP to the corresponding residues of PTH, we were able to convert PTHrP into a ligand that avidly bound to the PTH-2 receptor and fully and potently stimulated cAMP formation, Changing residue 23 alone yielded [Trp(23)]hPTHrP-(1-36), which was an antagonist for the PTH-2 receptor, but a fall agonist for the PTH/PTHrP receptor. Residues 5 and 23 in PTH and PTHrP thus play keg roles in signaling and binding interactions, respectively, with the PTH-2 receptor. Receptor-selective agonists and antagonists derived hom these studies could help to identify the biological role of the PTH-2 receptor and to map specific sites of ligand-receptor interaction.